333 related articles for article (PubMed ID: 15563360)
1. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.
Reginster JY; Gieschke R
Curr Drug Metab; 2006 Oct; 7(7):827-36. PubMed ID: 17073582
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
[TBL] [Abstract][Full Text] [Related]
4. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
[TBL] [Abstract][Full Text] [Related]
5. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
6. The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
Nakai K; Tobinai M; Hashimoto J; Iida S; Kawanishi T
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):139-47. PubMed ID: 25476995
[TBL] [Abstract][Full Text] [Related]
7. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
Ravn P; Neugebauer G; Christiansen C
Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604
[TBL] [Abstract][Full Text] [Related]
8. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
9. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
Ravn P; Clemmesen B; Riis BJ; Christiansen C
Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
[TBL] [Abstract][Full Text] [Related]
10. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Bauss F; Russell RG
Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
[TBL] [Abstract][Full Text] [Related]
11. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
[TBL] [Abstract][Full Text] [Related]
12. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
15. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
[TBL] [Abstract][Full Text] [Related]
17. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Epstein S
Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
[TBL] [Abstract][Full Text] [Related]
19. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
Binkley N; Silverman SL; Simonelli C; Santiago N; Kohles JD; Dasic G; Sunyecz JA
Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
Frampton JE; Perry CM
Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
